Emisphere Signs Research Agreement With Syracuse University

Emisphere and Syracuse University have entered into a research agreement to combine Emisphere’s Eligen oral drug delivery technology with a new oral drug delivery system developed in the laboratory of Robert Doyle, Syracuse University.

The experiments will test whether the combination of Eligen and Doyle’s oral drug delivery technology will enhance the absorption of an appetite-suppressing hormone.

Michael Novinski, President and CEO, Emisphere, said: Dr. Doyle and his colleagues have successfully developed innovative methods for the oral delivery of both proteins and peptides using novel methods. We, therefore, see a significant potential for innovation in this partnership and an opportunity for further expansion for the use of our Eligen Technology in the drug delivery arena.